An observational study in Radiotherapy Side Effect, sponsored by University of Aarhus. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by University of Aarhus · Observational
The study aims to provide a setup for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for all Danish cancer patients undergoing reirradiation with high dose intention or with the aim of local tumour control; with the ultimate aim of providing safe reirradiation to a larger group of patients. To build a reirradiation cohort database for future research
Reirradiation of recurrent or new tumours has been associated with high rates of severe and even lethal toxicity in some previous reports [Andratscske2023]. This has led to many patients not being offered high dose reirradiation, even though they may potentially benefit from effective local treatment. Thus, it is extremely important to establish solid evidence of the risk of severe toxicity, to enable radiotherapy to be offered to these patients on an equal footing with patients treated for their first cancer.
This prospective registration study will form the basis of a database enabling us to learn more about which patients are suitable for reirradiation, optimal constraints for organs at risk in reirradiation, overall survival, etc.
108 studies on the registry are indexed under Radiation Injuries; 46 are open to participants now.
This study's planned enrollment of 500 is above the median of 105 across 41 observational studies indexed under Radiation Injuries.
Browse Radiation Injuries studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
No guidelines are provided on the selection of patients for high dose reirradiation.
All patients are eligible for the database if treated with reirradiation with the aim of local control.
Read Danish (for questionnaires + patient information)
Life expectancy due to age and co-morbidity of ≥6 months.
The general condition must be sufficient to tolerate persistent significant side effects
Histological or imaging verified loco-regional recurrence, solitary oligo metastasis or new primary
Age ≥18 years
Signed informed consent, updated annually
Expected follow up physical, by video, by phone or likely contact at a relevant oncological department
Available dose plan(s) from primary (and prior) radiotherapy course(s) (with 3D reconstruction of previous plans, available port film, or drawings). Multiple re-treatments are allowed (new inclusion and baseline registration)
Exclusion Criteria:
Inability to attend full course of radiotherapy
Purpose of radiotherapy is ONLY palliation of symptoms
All patients treated with reirradiation with the aim of local control
Radiation: Reirradiation
reirradiation with all available modalities can be included
Side effects
CTCAE side effects
Time frame: 5 years
No study locations are listed for this record.
Plan to share: Undecided — A predefined central data analysis plan has not been established for this study. Instead, data analyses will primarily be undertaken within the framework of individual sub-projects, each of which must be reviewed and approved by the steering committee.
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus